Emerging Considerations in Immune Checkpoint Inhibitors: Esophago-Gastric Cancer

Access Course



This activity is intended for oncologists, gastroenterologists, and surgeons.


The goal of this activity is to discuss the evolving role of cancer immunotherapy in gastric and gastroesophageal junction cancer.







Approximate Time to Complete: 30 minutes


Credit Available: Nov. 29, 2017 - Nov. 29, 2018


Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the clinical trial data on the use of immune checkpoint inhibitors in advanced gastric cancer
  • Have increased knowledge regarding the which patients with advanced gastric cancer may be appropriate candidates for immune checkpoint modulation.
Accreditation Council For Continuing Medical Education
AMA PRA Category 1 Credit(s)™: 0.50
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.50